Valuation : Xencor, Inc.

Market Cap 1.98B 1.7B 1.6B 1.46B 2.74B 187B 2.74B 18.93B 7.35B 95.84B 7.43B 7.27B 309B P/E 2026 *
-8.65x
P/E 2027 * -8.24x
Enterprise Value 1.55B 1.33B 1.25B 1.14B 2.14B 146B 2.14B 14.79B 5.74B 74.87B 5.8B 5.68B 241B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 15.9x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day-0.04%
1 week+2.11%
Current month-2.40%
1 month+33.58%
3 months+121.57%
6 months+108.87%
Current year+73.81%
1 week 25.4
Extreme 25.4
28.98
1 month 19.07
Extreme 19.07
30.61
Current year 10.38
Extreme 10.375
30.61
1 year 8.19
Extreme 8.19
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/6/26 Free

Director

30,906 0.0417%
10/4/26 Sell

Chief Financial Officer

3,499 0.0048%
5/3/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%+2.11%+217.92%+18.64% 1.98B
-1.79%-2.27%+50.90%+89.03% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.31%+6.54%-11.39%+457.82% 27.66B
+0.86%+1.65%+0.25%-14.78% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-15.21%+210.71%+370.84% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
-0.20%+8.37%+57.87%+159.50% 14.65B
Average -1.24%-1.10%+63.08%+169.02% 28.52B
Weighted average by Cap. -1.52%-0.39%+43.77%+144.07%

Financials

2026 *2027 *
Net sales 143M 123M 116M 106M 198M 13.52B 199M 1.37B 532M 6.94B 538M 526M 22.35B 125M 107M 101M 92.24M 173M 11.78B 173M 1.19B 463M 6.04B 468M 458M 19.46B
Net income -240M -206M -194M -177M -332M -22.64B -333M -2.29B -890M -11.61B -900M -881M -37.41B -284M -245M -230M -210M -394M -26.86B -395M -2.72B -1.06B -13.78B -1.07B -1.04B -44.4B
Net Debt -433M -373M -351M -320M -599M -40.88B -601M -4.14B -1.61B -20.98B -1.63B -1.59B -67.57B -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
04/09/26 US$26.61 -0.04% 919,790
03/09/26 US$26.62 -1.04% 1,321,480
02/09/26 US$26.90 -3.62% 1,018,293
01/09/26 US$27.91 +2.37% 1,475,981
31/08/26 US$27.27 +4.62% 1,808,116
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.61USD
Average target price
30.08USD
Spread / Average Target
+13.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock